Sign In
Buy ATOS
$4.70
-0.150 (-3.09%)
At Close: Jun 03, 2026
Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations Trial-in-Progress Abstract Details Ongoing Pha
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) research SEATTLE, May 20, 2
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials SEATTLE, May 14, 2026 /PRNewswire/
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
08:45am, Friday, 08'th May 2026
SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas
Peer-reviewed data support (Z)-endoxifen's (Endoxifen) potential as a differentiated breast cancer risk prevention candidate by marked reduction of mammographic breast density (MBD) Doses of both 1 mg
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
08:30am, Monday, 04'th May 2026
Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval SEATTLE, May 4, 2026 /PRNewswire/ -- Atossa Ther
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
05:30pm, Wednesday, 25'th Mar 2026
SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other ar
Hyperfine (NASDAQ:HYPR) and Atossa Genetics (NASDAQ:ATOS) Critical Comparison
02:15am, Sunday, 22'nd Mar 2026
Hyperfine (NASDAQ: HYPR - Get Free Report) and Atossa Genetics (NASDAQ: ATOS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesse
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
11:00am, Thursday, 19'th Mar 2026
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary - Big money is moving back into biotech. Institutional investors have been writing some of the large
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
08:00am, Thursday, 19'th Mar 2026
Kathy Puyana Theall, M.D. and Adebola Giwa, M.D.
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
08:00am, Thursday, 12'th Mar 2026
Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic Mice SEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasda
Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus PT from Analysts
01:33am, Friday, 20'th Feb 2026
Shares of Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) have earned a consensus recommendation of "Hold" from the five research firms that are currently covering the firm, MarketBeat.com repor
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 29.7% in January
02:15am, Monday, 16'th Feb 2026
Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 4,696,759 shares, a growth
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
08:30am, Wednesday, 11'th Feb 2026
SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and othe
